Latest news with #DiFrancesco
Yahoo
25-05-2025
- Sport
- Yahoo
🤯 European spots and survival twists: all Serie A final day scenarios
This article was translated into English by Artificial Intelligence. You can read the original version in 🇮🇹 here. After assigning the Scudetto, the 38th matchday of Serie A will also deliver all the other missing verdicts. Let's see, objective by objective, what could happen. To assign the last available spot in the Champions League, match point for Juventus who, away from home against Venezia, have everything in their own hands. Tudor's team, by winning, would secure the fourth and last placement for the top European championship. Roma, one point behind the bianconeri, will have to win against Torino and hope for Venezia's feat. For Lazio, there is only arithmetic hope, but to finish fourth, they would need to win against Lecce and hope that both Juventus and Roma have a bad night. All the results, of course, are also intertwined for the Europa League and Conference positions. Given that Bologna has already qualified thanks to the Coppa Italia, Lazio must attack Roma's fifth place, but also avoid the blow with Fiorentina. The Viola are 3 points behind and to catch up with Lazio, they must win and hope for a biancoceleste knockout: in this case, Conference (yet another) for Palladino's team and Lazio out of everything. JUVENTUS 67 ROMA 66 LAZIO 65 FIORENTINA 62 The survival struggle, on the other hand, is much more tense and with significant entanglements. Venezia is with one and a half feet in Serie B. Di Francesco's team, to save themselves, must beat Juventus and hope that Lecce and Empoli lose. The Tuscans will have to deal with a Verona that, unless there are sensational twists, is the one that is slightly better off and risks less being sucked into the vortex of B, while Lecce will go to the Olimpico with Lazio. Reaching equal points would mean a playoff. Parma is also at risk: in the event of a defeat against Atalanta and a consequent double success of Empoli and Lecce, the ducals would be sensationally in B. VERONA 34 PARMA 33 EMPOLI 31 LECCE 31 VENEZIA 29 📸 Alessandro Sabattini - 2025 Getty Images
Yahoo
29-04-2025
- Sport
- Yahoo
GdS: ‘The 3-4-3 works' – how Milan secured solid but unspectacular win over Venezia
AC Milan got another win and another clean sheet on Sunday against Venezia, and it was further proof that the new system is working well. This morning's edition of La Gazzetta dello Sport (seen below) recalls how Milan returned from Venice with three points, got Santiago Gimenez scoring again, and earned confirmation that the new formation has fixed a few faults. Moreover, the race for the European spots is not yet over. Advertisement However, it was not a romantic gondola ride. The 2-0 victory was one that the Rossoneri had to work hard for even though they took the lead after just a few minutes. There was lots of pragmatism, and some help from Youssouf Fofana. Anonymous Venezia Venezia show good things in the build-up phase and they often move the ball well vertically, but they have little precision in front of goal and defensively they are found lacking. One of those cases in which the statistics tell a clear truth: they score 60 percent of their goals from set pieces, the best in Serie A, but in open play goals they are the last. The only real shot on goal is, in fact, a free kick by Nicolussi Caviglia. Just one goal in the last six home games. Advertisement If Di Francesco doesn't light up the attack in this final part of the season, the situation becomes dangerous. The last few rounds had given a bit of hope: draws against Napoli, Lazio and Atalanta. But Milan were more clinical and this defeat hurts. Image: AC Milan Pulisic goal Milan started well, a 3-4-3 that was hard to decipher thanks to Pulisic who escaped any tactical classification and the opponents: he filled the centre as a midfielder, moved into the middle aligning himself with Abraham as a centre-forward, cut inside, took a touch and finished. It was the other top player of the day, Fofana, who took advantage of a misplaced pass as Venezia tried to play out of the back, receiving the ball and finding the run of the American in behind. Advertisement The manifesto of success was in the beautiful dialogue between the two and in Venezia's imbalances. Luka Jovic got hurt in the warm-up: Abraham opened up more spaces, but he didn't have the goal-scoring sense of the Serbia. Yeboah unleashed It's not that Milan have found the formula for happiness: the performance seen in Venezia is not enough for the final against Bologna, especially if Leao turns off the light after a couple of runs. By now Conceiçao's safety system is this 3-4-3, but more consistency and personality are needed. The slowdown allowed Venezia to reorganise after the start with disconnected departments and a dangerously high defence when Milan were countered on. Advertisement Di Francesco compacts his team: on the right Yeboah always ran at his man with speed, scaring Pavlovic. On the other side, Candé and Haps began to understand each other, exposing some of Jimenez's defensive limitations. Zerbin, Yeboah and Nicolussi almost scored, Yeboah scored from a Candé-Haps assist: disallowed for an offside on Busio at the start of the action, yet the fact remains that Milan were not protected. la gazzetta dello sport 28 april venezia Gimenez is back Di Francesco tried to redesign Venezia: Gytkjaer as a striker for Fila was the correct late move, then Oristanio in place of Conde transformed the system into a 3-4-2-1 that could have been thought of before. Advertisement Milan no longer created danger and so Conceiçao chooses to protect himself with Walker for Jimenez and Loftus-Cheek in place of Leao: formally it was 3-4-3, but the intent to close up shop with five was undeniable. In the heat of the finale, Venezia pushed high and Reijnders found Gimenez with a ball from 50 metres away, finished with a lob to make it a 2-0 win that in truth the game probably did not reflect. It was a goal that was useless for the result, but of huge importance if it gives a jolt to the Mexican who has been on a siesta. Italian football is different from Dutch football, but Gimenez is not the ghost of recent times.
Yahoo
27-04-2025
- Sport
- Yahoo
VENEZIA v AC MILAN: MATCH PREVIEW
AC Milan are getting ready to face Venezia on Serie A 2024/25 Matchday 34. The game will be played on Sunday 27 April at 12:30 CEST at the historic Pier Luigi Penzo Stadium. Conceição's boys are looking to climb the table and to keep the European charge open until the very end, while Di Francesco's side are aiming to take points to help them in their difficult fight for safety. With both teams in need of precious points, we are expecting a competitive match. This is Serie A, and this is our Matchday 34 Match Preview. LATEST FROM MILANELLO The last league outing was our defeat to Atalanta at San Siro, but our game in Venice will close out a special week after beating Inter 3-0 in Coppa Italia, and securing our place in the final in Rome against Bologna. It is a period of ups and downs, but you can feel the Rossoneri's determination to improve their position in the table. The goal is to get back to winning ways in the league, and AC Milan will give their all against Venezia with an almost fully-fit squad. The only unavailable player are Emerson Royal who has been suffering with a long-term injury while Matteo Gabbia is a doubt. If a 3-4-3 were to be used, Thiaw would take his place, and it is possible that there may be some rotations from the derby on Wednesday, particularly with the availability of Loftus-Cheek and Walker. We have three cautions: Bondo, Hernández and Leão. LATEST FROM VENEZIA It has been a tough campaign for the Neroverdi, who have been in the relegation zone since the start of the season. Their recent form has been positive though: only one loss in their last eight matches - 0-1 against Bologna - and in that time they have drawn 0-0 with Atalanta, Lazio and Napoli (the last two at home). Safety is just one point away and all three points would see them overtake Lecce and get away from Empoli, at least for a few hours. Fila coming back from suspension is important as he will be ready to take his place in the attacking duo alongside one of either Yeboah or Oristanio, with the former as the favourite. They also almost have a full team, besides Sagrado and Svoboda with long-term issues, with Nicolussi Caviglia now in good condition. Idzes and Kike Pérez are cautioned. Advertisement "AC Milan have had some good points, and others not so much, but I am sure they will want to build on the derby knowing their coach", said Eusebio Di Francesco in his press conference. "We must focus on ourselves, on our attitude and determination, knowing that we are facing one of this league's big teams. In an attacking sense, they are the most dangerous team, they have great threats. We will try to be ready for everything, also for possible changes". PRE-MATCH NUMBERS AC Milan are unbeaten in 13 of their last 14 meetings with Venezia in Serie A (11W, 2D, including a game won by forfeit). The Rossoneri have won all of their last four matches against Venezia in Serie A, keeping a clean sheet in the three most recent games; AC Milan, however, have never registered three clean sheets against the Neroverdi in Serie A. The last draw between Venezia and AC Milan in Venice in Serie A dates back to 4 May 1947 (1-1). Since then, there have been six Rossoneri wins and two for the home side. The Neroverdi are the team that have drawn the most games in Serie A in 2025: 9 out of 15 (1W, 5L). Venezia are the team with the highest percentage of goals from set pieces in Serie A 2024/25: 59% (16/27). However, they are also the team with the least number of open-play goals this season (11). Theo Hernández has scored more goals against Venezia than any other team in Serie A: four in three games, including a brace in the only match that he played at the Penzo (9 January 2022). AC Milan's full back has 31 total goals in the league, only two defenders have more goals for a single team in Serie A: Giacinto Facchetti (59 for Inter), and Antonio Cabrini (33 for Juventus). WHERE TO WATCH VENEZIA v AC MILAN In Italy, the game will be broadcast on DAZN. To watch it in a different country, you can check the "Where to Watch AC Milan on TV" section under "Abroad." On the Rossoneri channels, the Matchday coverage on Milan TV will begin at 11:45 CEST, leading up to kick-off, followed by interviews and a press conference with Coach Conceição. Don't miss the coverage on the AC Milan Official App, official social media channels and WhatsApp. Advertisement LATEST FROM SERIE A Manganiello from Pinerolo, with 108 matches in charge in Serie A, will be the referee for Venezia v AC Milan. He has refereed nine games for the Rossoneri, including two this season: Como 1-2 AC Milan and AC Milan 1-2 Lazio. The assistants will be Berti and Bahri, with fourth official Galipò, as well as VAR Paterna and AVAR Sozza. The schedule for Matchday 34 changed compared to the original plan, because of the national mourning of the death of Pope Francis and the loss of Lecce's physiotherapist. Venezia v AC Milan will open the weekend at the same time as Como v Genoa on Sunday at 12:30 CEST. At 15:00 CEST there will be Fiorentina v Empoli and Inter v Roma, with Juventus v Monza at 18:00 CEST, and Atalanta v Lecce as well as Napoli v Torino at 20:45 CEST. There will be three games to close the matchday on Monday: Udinese v Bologna will be played at 18:30 CEST, with Hellas Verona v Cagliari and Lazio v Parma at 20:45 CEST. The table: Inter and Napoli 71; Atalanta 64; Bologna 60; Juventus and Lazio 59; Roma 57; Fiorentina 56; AC Milan 51; Torino 43; Udinese 40; Como and Genoa 39; Hellas Verona 32; Parma 31; Cagliari 30; Lecce 26; Venezia and Empoli 25; Monza 15. Join the AC Milan WhatsApp channel!
Globe and Mail
14-04-2025
- Health
- Globe and Mail
Paladin Pharma and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Public Funding of XCOPRI® (cenobamate tablets)
MONTREAL , /CNW/ -- Paladin Pharma is pleased to announce the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public funding of XCOPRI ® (cenobamate tablets) as adjunctive therapy in the management of focal seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. 1 "We are pleased to have successfully concluded the negotiation process with the pCPA," said Livio Di Francesco , Vice President & General Manager of Paladin Pharma. "This is a significant milestone to ensure that appropriate Canadian epilepsy patients have broad and equitable access to XCOPRI, and it is exciting news for the epilepsy community across Canada ." Since launch, the Paladin team has already achieved early access for XCOPRI through private payer reimbursement, with approximately 85% of privately insured lives in Canada having access to the treatment. The next step in the public reimbursement process will be for provincial, territorial, and federal government organizations to make their respective final decisions on public reimbursement for their regions. Paladin looks forward to working with each of them to make XCOPRI available as soon as possible through public drug plans. "We hope the jurisdictions move as quickly as possible," added Di Francesco . "Uncontrolled epilepsy can have a significant impact on a patient's life, and we look forward to the day when all appropriate patients in Canada can have access to this important treatment option." About Epilepsy 2-4 Epilepsy is a chronic neurological condition affecting ~300,000 Canadians. It is characterized by recurrent, unprovoked seizures. While there are many different types of seizures, they can be grouped into two broad categories – generalized seizures and focal seizures – based on where in the brain the seizure activity starts. Focal seizures (also called partial-onset seizures) affect ~60% of people with epilepsy. While many people with epilepsy respond to anti-seizure medication, ~30% of patients continue to experience seizures, despite treatment with currently available medication options. About XCOPRI XCOPRI received Health Canada approval in June 2023 for use as adjunctive therapy in the management of focal seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. It is taken orally, once daily. 5 XCOPRI is a new generation of anti-seizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK Life Science. It is a novel molecule with a dual mechanism of action. In pre-clinical studies, XCOPRI has been demonstrated to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a modulator of the γ-aminobutyric acid (GABAA) ion channel. 5-6 The efficacy and safety of XCOPRI for the treatment of adults with uncontrolled partial-onset seizures (also known as focal-onset seizures) were assessed in two randomized, placebo-controlled, double-blind clinical trials (C013 and C017). 6-7 The long-term safety of cenobamate in this population has been studied in an open-label safety study (C021). 8 During Studies C013 and C017, a total of 441 patients were exposed to XCOPRI. In both studies, the primary efficacy endpoint was median percent reduction from baseline in seizure frequency per 28 days. The key secondary endpoint was responder rates, defined as the proportion of patients with 50% or greater reduction in seizure frequency. XCOPRI significantly reduced seizure frequency and demonstrated a significantly higher ≥50% responder rate compared to placebo. In Study C013, 28.3% of patients in the cenobamate group reported being seizure free during the maintenance phase (placebo: 8.8%). Consult the Product Monograph for complete efficacy and safety information. Cenobamate is currently marketed in the U.S. as XCOPRI ® and in Europe under the trademark ONTOZRY ®. About Paladin Pharma Paladin Pharma Inc., headquartered in Montreal, Canada , is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing, medical, and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies. Paladin is an operating company of Endo, Inc. For more information visit Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the statements by Mr. Di Francesco and any statements relating to marketing approval, public funding and reimbursement, product efficacy, potential treatments or indications, therapeutic outcomes or treatment responses, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Paladin's or Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Paladin and Endo may not currently be able to predict. Although Paladin and Endo believe that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: changes in competitive, market or regulatory conditions; changes in legislation or regulations; the ability to obtain and maintain adequate protection for intellectual property rights; the impacts of competition; the timing and uncertainty of the results of the public funding processes; health care and cost containment reforms, including government pricing, tax and reimbursement policies; litigation and other disputes; consumer and physician acceptance of current and new products; the performance of third parties upon whom we rely for goods and services; issues associated with our supply chain; the ability to develop and expand our product pipeline, to launch new products and to continue to develop the market for our products; and the effectiveness of advertising and other promotional campaigns. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-K and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A. References: pCPA, "Xcopri (cenobamate)", available at Xcopri (cenobamate) | pCPA Accessed April 4, 2024 Canadian Epilepsy Alliance. Accessed April 4, 2024 . Public Health Agency of Canada . Epilepsy in Canada . 2021. Accessed April 4, 2025 . Epilepsy Canada . Accessed April 4, 2025 . XCOPRI ® Product Monograph. Paladin Pharma Inc. May 15, 2024 . Chung SS, et al. Neurology. 2020;94:e2311-e2322. Krauss GL, et al. Lancet Neurol. 2020;19:38-48. Sperling MR, et al. Epilepsia. 2020;61(6):1099-1108.
Associated Press
14-04-2025
- Health
- Associated Press
Paladin Pharma and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Public Funding of XCOPRI® (cenobamate tablets)
MONTREAL, April 14, 2025 /CNW/ -- Paladin Pharma is pleased to announce the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public funding of XCOPRI® (cenobamate tablets) as adjunctive therapy in the management of focal seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.1 'We are pleased to have successfully concluded the negotiation process with the pCPA,' said Livio Di Francesco, Vice President & General Manager of Paladin Pharma. 'This is a significant milestone to ensure that appropriate Canadian epilepsy patients have broad and equitable access to XCOPRI, and it is exciting news for the epilepsy community across Canada.' Since launch, the Paladin team has already achieved early access for XCOPRI through private payer reimbursement, with approximately 85% of privately insured lives in Canada having access to the treatment. The next step in the public reimbursement process will be for provincial, territorial, and federal government organizations to make their respective final decisions on public reimbursement for their regions. Paladin looks forward to working with each of them to make XCOPRI available as soon as possible through public drug plans. 'We hope the jurisdictions move as quickly as possible,' added Di Francesco. 'Uncontrolled epilepsy can have a significant impact on a patient's life, and we look forward to the day when all appropriate patients in Canada can have access to this important treatment option.' About Epilepsy 2-4 Epilepsy is a chronic neurological condition affecting ~300,000 Canadians. It is characterized by recurrent, unprovoked seizures. While there are many different types of seizures, they can be grouped into two broad categories – generalized seizures and focal seizures – based on where in the brain the seizure activity starts. Focal seizures (also called partial-onset seizures) affect ~60% of people with epilepsy. While many people with epilepsy respond to anti-seizure medication, ~30% of patients continue to experience seizures, despite treatment with currently available medication options. About XCOPRI XCOPRI received Health Canada approval in June 2023 for use as adjunctive therapy in the management of focal seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. It is taken orally, once daily.5 XCOPRI is a new generation of anti-seizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK Life Science. It is a novel molecule with a dual mechanism of action. In pre-clinical studies, XCOPRI has been demonstrated to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a modulator of the γ-aminobutyric acid (GABAA) ion channel.5-6 The efficacy and safety of XCOPRI for the treatment of adults with uncontrolled partial-onset seizures (also known as focal-onset seizures) were assessed in two randomized, placebo-controlled, double-blind clinical trials (C013 and C017).6-7 The long-term safety of cenobamate in this population has been studied in an open-label safety study (C021).8 During Studies C013 and C017, a total of 441 patients were exposed to XCOPRI. In both studies, the primary efficacy endpoint was median percent reduction from baseline in seizure frequency per 28 days. The key secondary endpoint was responder rates, defined as the proportion of patients with 50% or greater reduction in seizure frequency. XCOPRI significantly reduced seizure frequency and demonstrated a significantly higher ≥50% responder rate compared to placebo. In Study C013, 28.3% of patients in the cenobamate group reported being seizure free during the maintenance phase (placebo: 8.8%). Consult the Product Monograph for complete efficacy and safety information. Cenobamate is currently marketed in the U.S. as XCOPRI® and in Europe under the trademark ONTOZRY®. About Paladin Pharma Paladin Pharma Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing, medical, and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies. Paladin is an operating company of Endo, Inc. For more information visit Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the statements by Mr. Di Francesco and any statements relating to marketing approval, public funding and reimbursement, product efficacy, potential treatments or indications, therapeutic outcomes or treatment responses, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plan,' 'will,' 'may,' 'look forward,' 'intends,' 'guidance,' 'future,' 'potential' or similar expressions are forward-looking statements. Because these statements reflect Paladin's or Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Paladin and Endo may not currently be able to predict. Although Paladin and Endo believe that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: changes in competitive, market or regulatory conditions; changes in legislation or regulations; the ability to obtain and maintain adequate protection for intellectual property rights; the impacts of competition; the timing and uncertainty of the results of the public funding processes; health care and cost containment reforms, including government pricing, tax and reimbursement policies; litigation and other disputes; consumer and physician acceptance of current and new products; the performance of third parties upon whom we rely for goods and services; issues associated with our supply chain; the ability to develop and expand our product pipeline, to launch new products and to continue to develop the market for our products; and the effectiveness of advertising and other promotional campaigns. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading 'Risk Factors' in Endo's most recent Form 10-K and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A. References: SOURCE Paladin Pharma Inc.
